New Drug For Duchenne Muscular Dystrophy With Dr. Steven Quay
About this episode
In this episode, Dr. Steven Quay discusses a new approach to treating Duchenne muscular dystrophy and the potential for innovation in medicine.
Send us Fan Mail In this episode of Rare Connection, I’m joined by physician-scientist and biotech CEO Dr. Steven Quay to discuss an emerging approach to treating Duchenne muscular dystrophy—and how innovation in one area of medicine may open doors for others. Dr. Quay is the CEO of Atossa Therapeutics, where his team is developing (Z)-endoxifen, a next-generation endocrine therapy originally studied in breast cancer. Unlike tamoxifen, which must be metabolized in the body, (Z)-endoxifen deli...
More episodes of Rare Connection
- McCune Albright Syndrome With Dr. Giwa From Atossa Therapeutics
- Adrenoleukodystrophy With Elisa From New York
- 26 Year Stomach Cancer Survivor Healing with Food with Chef Chuck
- Denovo (Genetic But Not Inhereited) With Jenny From Texas
- Schizencephaly with Glen from California
- Atypical Hemolytic Uremic Syndrome With Taylor From California
Explore listener stats, chart rankings, contacts and more on the Rare Connection podcast page.